Skip to main
CSTL

CSTL Stock Forecast & Price Target

CSTL Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Castle Biosciences Inc. has demonstrated impressive growth metrics, particularly with its TissueCypher test, which experienced a 92% year-over-year increase in test volume in 2Q25, indicating strong market demand and effective sales force expansion. The company has also maintained robust profit margins, with TissueCypher achieving gross margins of 77% in Q3, reflecting the financial health and efficiency of its operations. As the gastrointestinal sales force matures in the second half of 2025, the potential for continued revenue growth from TissueCypher is strong, positioning Castle Biosciences favorably within its market segments.

Bears say

Castle Biosciences Inc. faces a negative outlook due to a projected decline in revenue multiples for its dermatology and DecisionDx-UM tests, primarily driven by the DecisionDx-Melanoma product, which is expected to be lower than those for TissueCypher. Despite indications that the stock appears undervalued in various scenarios, management has acknowledged significant barriers to market penetration, specifically the lack of awareness among clinicians in the gastroenterology sector regarding their tests. Additionally, it is believed that investor sentiment currently underestimates the challenges associated with expanding awareness and adoption of Castle's key test solutions.

CSTL has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Castle Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Castle Biosciences Inc (CSTL) Forecast

Analysts have given CSTL a Buy based on their latest research and market trends.

According to 6 analysts, CSTL has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Castle Biosciences Inc (CSTL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.